Adults aged more than 70 who received more prescriptions for nirmatrelvir-ritonavir did not show decreased rates of ...

The antiviral pill Paxlovid does not significantly reduce COVID-19 hospitalizations in vaccinated older adults, according to ...

The authors compared outcomes among adults just under 70 years who were not prescribed Paxlovid to those who were given the ...

Paxlovid may not decrease the risk for hospitalization or death in older adults vaccinated against COVID-19 as much as ...

Still, Mafi says there aren't strong data on how Paxlovid affects the disease course in people who are vaccinated. His findings suggest that the benefits are about four times smaller than those ...

Paxlovid does not significantly reduce COVID-19 hospitalization and mortality among vaccinated older adults, according to new ...

COVID-19 treatment called into question after major study In a nutshell A major study of 1.6 million seniors found that ...

A new analysis of health data from Ontario, Canada, suggests that nirmatrelvir-ritonavir (Paxlovid) may provide limited benefit for vaccinated older adults with COVID-19, despite its previously proven ...

Paxlovid may offer marginal benefits for low-risk children with COVID-19; however, among high-risk children with COVID-19, Paxlovid is a safe oral option.

Long COVID duration did not affect health outcomes; however, COVID-19 vaccination status was associated with better PROMIS ...